Processa Pharmaceuticals (PCSA) Other financing activities (2018 - 2021)

Processa Pharmaceuticals (PCSA) has reported Other financing activities for 3 consecutive years, with -$27980.0 the latest figure, recorded in Q3 2021.

• For the quarter ending Q3 2021, Other financing activities rose 92.15% year-over-year to -$27980.0; the trailing twelve-month figure through Sep 2021 stood at $9.5 million (up 2428.92% YoY), and the FY2018 full-year result was -$168457.0, down 174.0% from the prior year.
• Other financing activities fell to -$27980.0 in Q3 2021 per PCSA's latest filing, from $9.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $9.9 million in Q1 2021 and bottomed at -$356416.0 in Q3 2020.
• Historically, Other financing activities has averaged $2.4 million across 3 years, with a median of -$39549.0 in 2018.
• The widest YoY moves for Other financing activities: up 92.15% in 2021, down 92.15% in 2021.
• Over 3 years, Other financing activities stood at -$51118.0 in 2018, then plunged by 597.24% to -$356416.0 in 2020, then jumped by 92.15% to -$27980.0 in 2021.
• According to Business Quant data, Other financing activities over the past three periods registered -$27980.0, $9.9 million, and -$356416.0 for Q3 2021, Q1 2021, and Q3 2020 respectively.